October 21, 2022 05:59 AM EDTUpdated 07:27 AM

Former Allergan exec heads to Revance as it challenges Botox; Mark Pruzanski surrounds himself with more teammates

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ Revance feels like it has a competitive advantage over AbbVie’s blockbuster Botox with only biannual injections of its freshly approved Daxxify, as opposed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Former Allergan exec heads to Revance as it challenges Botox; Mark Pruzanski surrounds himself with more teammates

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Exclusive: Florida cancer biotech raises $100M Series A

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

For­mer Al­ler­gan ex­ec heads to Re­vance as it chal­lenges Botox; Mark Pruzan­s­ki sur­rounds him­self with more team­mates

Copy Chief

Editor

Sign up to read this article for free.

more like this

Former Allergan exec heads to Revance as it challenges Botox; Mark Pruzanski surrounds himself with more teammates